What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM)
DOI:
https://doi.org/10.46765/2675-374X.2020v1n1p27-29Abstract
Patients with multiple myeloma (MM) in clinical conditions to be referred to autologous hematopoietic stem cell transplantation (AHSCT) generally start therapy with an induction chemotherapy followed by high-dose alkylating and AHSCT. The ideal regimen and the number of pre-AHSCT induction is still a controversial subject, however, opting for at least three to four cycles of chemotherapy including a drug with immunomodulatory action, a proteasome inhibitor, with a corticosteroid, are advised as the first line before AHSCT.